Summit Therapeutics (SMMT) Reports Q3 Loss of GBP0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Summit Therapeutics (SMMT) Remains an Under-the-Radar DMD Play to Watch - Oppenheimer
December 18, 2015 12:57 PM ESTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Summit Therapeutics plc (NASDAQ: SMMT), saying the stock remains an under-the-radar DMD play.
Marai commented, "On 12/17, Summit reported F3Q15 results, ending the quarter with £22.2M in cash. Given its... More
